As rates of epilepsy continue to climb, drug developers have cut back in research in this area, many are deterred by the large number of existing drugs and off-patent drugs on the market, the challenge of large clinical trials and unclear financial rewards.
The past decade has seen little by way of new treatment for epilepsy, and existing medications can come with significant adverse reactions. Given this, biopharmaceutical companies need to take a different course to improve treatments for people with seizure disorders. For many developers, taking a rare-disease approach may be the answer.
The latest white paper by Back Bay Life Science Advisors looks at how and why biopharmaceutical companies are focusing on smaller, underserved patient pools with high unmet need with the expectation that the broader epilepsy community may ultimately benefit.